Prevention of dipyrone (metamizole) induced inhibition of aspirin antiplatelet effects

Summary

We have recently shown that dipyrone (metamizole), a non-opioid analgesic, can nullify aspirin (acetylsalicylic acid; ASA) antiplatelet effects in patients with coronary artery disease (CAD). In this study, we analysed the aspirin and dipyrone drug-drug interaction in order to identify strategies to prevent the dipyrone induced inhibition of asprin antiplatelet effects. Platelet function was measured by arachidonic acid-induced light-transmission aggregometry, thromboxane (TX) B2–formation by immunoassay. Dipyrone metabolite plasma levels were determined by high-performance-liquid-chromatography (HPLC). In seven healthy individuals, in vitro ASA (30 μM/ 100 μM/ 300 μM/ 1,000 μM) and dipyrone (10 μM) coincubation revealed, that the aspirin and dipyrone interaction can be overcome by increasing doses of aspirin. In 36 aspirin and dipyrone comedicated CAD patients, addition of ASA (30 μM/ 100 μM) in vitro inhibited, but did not completely overcome the dipyrone induced reduction of aspirin antiplatelet effects. Notably, the inhibition of thromboxane formation in aspirin and dipyrone comedicated CAD patients coincided with dipyrone plasma levels. In a cross-over designed study in four healthy individuals, we were able to prove that inhibition of aspirin (100 mg/ day) effects by dipyrone (750 mg/ day) was reversible. Furthermore, aspirin (100 mg/ day) medication prior to dipyrone (750 mg/ day) intake prevented the inhibition of antiplatelet effects by dipyrone in 12 healthy individuals. In conclusion, aspirin medication prior to dipyrone intake preserves antiplatelet effects, circumventing the pharmacodynamic drug-drug interaction at the level of cyclooxygenase-1.

Clinical Trial Registration: NCT01402804; http://clinicaltrials.gov/ct2/show/NCT01402804.

Keywords

Aspirin - coronary artery disease - platelets - dipyrone - metamizole

• References

• 1 Reid KJ, Harker J, Bala MM. et al. Epidemiology of chronic non-cancer pain in europe: Narrative review of prevalence, pain treatments and pain impact. Curr Med Res Opin 2011; 27: 449-462.
• 2 van Hecke O, Torrance N, Smith BH. Chronic pain epidemiology and its clinical relevance. Br J Anaesth 2013; 111: 13-18.
• 3 Saxena A, Balaramnavar VM, Hohlfeld T. et al. Drug/drug interaction of common nsaids with antiplatelet effect of aspirin in human platelets. Eur J Pharmacol 2013; 721: 215-224.
• 4 Trzos E, Uznanska B, Rechcinski T. et al. Myocardial infarction in young people. Cardiol J 2009; 16: 307-311.
• 5 Raftery MN, Sarma K, Murphy AW. et al. Chronic pain in the republic of ireland--community prevalence, psychosocial profile and predictors of pain-related disability: Results from the prevalence, impact and cost of chronic pain (prime) study, part 1. Pain 2011; 152: 1096-1103.
• 6 Gislason GH, Jacobsen S, Rasmussen JN. et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906-2913.
• 7 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
• 8 Uchiyama S, Nakamura T, Yamazaki M. et al. New modalities and aspects of antiplatelet therapy for stroke prevention. Cerebrovasc Dis 2006; 21 (Suppl. 01) 7-16.
• 9 Hohlfeld T, Weber AA, Junghans U. et al. Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007; 24: 43-50.
• 10 Mueller MR, Salat A, Stangl P. et al. Variable platelet response to low-dose asa and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997; 78: 1003-1007.
• 11 Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: New aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg 2008; 34: 93-108.
• 12 Catella-Lawson F, Reilly MP, Kapoor SC. et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345: 1809-1817.
• 13 Capone ML, Sciulli MG, Tacconelli S. et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 2005; 45: 1295-1301.
• 14 Schuijt MP, Huntjens-Fleuren HW, de Metz M. et al. The interaction of ibuprofen and diclofenac with aspirin in healthy volunteers. Br J Pharmacol 2009; 157: 931-934.
• 15 Rimon G, Sidhu RS, Lauver DA. et al. Coxibs interfere with the action of aspirin by binding tightly to one monomer of cyclooxygenase-1. Proc Natl Acad Sci USA 2010; 107: 28-33.
• 16 Hohlfeld T, Saxena A, Schror K. High on treatment platelet reactivity against aspirin by non-steroidal anti-inflammatory drugs – pharmacological mechanisms and clinical relevance. Thromb Haemost 2013; 109 (05) 825-833.
• 17 Laporte JR, Carne X, Vidal X. et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan countries study on upper gastrointestinal bleeding. Lancet 1991; 337: 85-89.
• 18 Schwabe UP. D. Arzneiverordnungs-report 2013: Aktuelle daten, kosten, trends und kommentare. Berlin Heidelberg, Springer;: 2011
• 19 Nikolova I, Petkova I, Tencheva J. et al. Metamizole: A review profile of a well-known “forgotten” drug. Part ii: Clinical profile. Biotechnology & Biotechno-logical Equipment 2014; 27: 3605-3619.
• 20 Garcia S, Canionero M, Lopes G. Dipyrone-induced granulocytopenia: A case for awareness. Pharmacotherapy 2006; 26: 440-442.
• 21 Polzin A, Zeus T, Schrör K. et al. Dipyrone (metamizole) can nullify the antiplatelet effect of aspirin in patients with coronary artery disease. J Am Coll Cardiol 2013; 62: 1725-1726.
• 22 Hinz B, Cheremina O, Bachmakov J. et al. Dipyrone elicits substantial inhibition of peripheral cyclooxygenases in humans: New insights into the pharmacology of an old analgesic. FASEB J 2007; 21: 2343-2351.
• 23 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
• 24 Frontroth JP. Light transmission aggregometry. Methods Mol Biol 2013; 992: 227-240.
• 25 Schror K, Seidel H. Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay system. Naunyn Schmiedeberg Arch Pharmacol 1988; 337: 177-182.
• 26 Shah S, Vanclay F, Cooper B. Improving the sensitivity of the barthel index for stroke rehabilitation. J Clin Epidemiol 1989; 42: 703-709.
• 27 Hohlfeld T, Zimmermann N, Weber AA. et al. Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 2008; 06: 166-173.
• 28 Montalescot G, Sechtem U, Achenbach S. et al. 2013 esc guidelines on the management of stable coronary artery disease: The task force on the management of stable coronary artery disease of the european society of cardiology. Eur Heart J 2013; 34: 2949-3003.